{"id":"https://openalex.org/W4394101899","doi":"https://doi.org/10.6084/m9.figshare.21583287","title":"Supplementary Material for: Effectiveness and Safety of Golimumab in the Treatment of Ulcerative Colitis: 52-week Results from Post-marketing Surveillance in Japan","display_name":"Supplementary Material for: Effectiveness and Safety of Golimumab in the Treatment of Ulcerative Colitis: 52-week Results from Post-marketing Surveillance in Japan","publication_year":2022,"publication_date":"2022-01-01","ids":{"openalex":"https://openalex.org/W4394101899","doi":"https://doi.org/10.6084/m9.figshare.21583287"},"language":"en","primary_location":{"id":"pmh:oai:figshare.com:article/21583287","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/dataset/Supplementary_Material_for_Effectiveness_and_Safety_of_Golimumab_in_the_Treatment_of_Ulcerative_Colitis_52-week_Results_from_Post-marketing_Surveillance_in_Japan/21583287","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Dataset"},"volume":null,"type":"supplementary-materials","is_traditional":false,"indexed_in":["datacite"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://figshare.com/articles/dataset/Supplementary_Material_for_Effectiveness_and_Safety_of_Golimumab_in_the_Treatment_of_Ulcerative_Colitis_52-week_Results_from_Post-marketing_Surveillance_in_Japan/21583287","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5062739693","display_name":"Shir\u00f4 Nakamura","orcid":"https://orcid.org/0000-0003-4435-1294","observed_orcids":["https://orcid.org/0000-0003-4435-1294"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S., Nakamura","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028583663","display_name":"Teita Asano","orcid":"https://orcid.org/0000-0002-1830-4382","observed_orcids":["https://orcid.org/0000-0002-1830-4382"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"T., Asano","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071140861","display_name":"Yasuyoshi Tanaka","orcid":"https://orcid.org/0000-0002-9053-4342","observed_orcids":["https://orcid.org/0000-0002-9053-4342"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Y., Tanaka","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5114144839","display_name":"Kentaro Sugimoto","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"K., Sugimoto","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040526542","display_name":"Shinichi Yoshigoe","orcid":"https://orcid.org/0000-0003-2704-054X","observed_orcids":["https://orcid.org/0000-0003-2704-054X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"S., Yoshigoe","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5101787157","display_name":"Yasuo Suzuki","orcid":"https://orcid.org/0000-0002-9813-9793","observed_orcids":["https://orcid.org/0000-0002-9813-9793"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Y., Suzuki","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10134","display_name":"Inflammatory Bowel Disease","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2715","display_name":"Gastroenterology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10134","display_name":"Inflammatory Bowel Disease","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2715","display_name":"Gastroenterology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10200","display_name":"Rheumatoid Arthritis Research and Therapies","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.0,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/golimumab","display_name":"golimumab","score":1.0},{"id":"https://openalex.org/keywords/ulcerative-colitis","display_name":"ulcerative colitis","score":1.0},{"id":"https://openalex.org/keywords/clinical-remission","display_name":"clinical remission","score":0.8489999771118164},{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.9620000123977661},{"id":"https://openalex.org/keywords/medication-persistence","display_name":"treatment persistence","score":0.8429999947547913},{"id":"https://openalex.org/keywords/corticosteroids","display_name":"corticosteroids","score":0.7699999809265137},{"id":"https://openalex.org/keywords/smoking","display_name":"smoking","score":0.8859999775886536},{"id":"https://openalex.org/keywords/biologic-naive-patients","display_name":"biologic-naive patients","score":0.8330000042915344},{"id":"https://openalex.org/keywords/biologic-experienced-patients","display_name":"biologic-experienced patients","score":0.8899999856948853},{"id":"https://openalex.org/keywords/comorbidity","display_name":"comorbidities","score":0.9100000262260437},{"id":"https://openalex.org/keywords/real-world-effectiveness","display_name":"real-world effectiveness","score":0.7459999918937683},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.5690000057220459},{"id":"https://openalex.org/keywords/post-marketing-surveillance","display_name":"post-marketing surveillance","score":0.7239999771118164}],"concepts":[{"id":"https://openalex.org/C2781290027","wikidata":"https://www.wikidata.org/wiki/Q413879","display_name":"Golimumab","level":4,"score":0.9580823183059692},{"id":"https://openalex.org/C2780479503","wikidata":"https://www.wikidata.org/wiki/Q1477","display_name":"Ulcerative colitis","level":3,"score":0.7353065609931946},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4518458843231201},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.3544994294643402},{"id":"https://openalex.org/C162853370","wikidata":"https://www.wikidata.org/wiki/Q39809","display_name":"Marketing","level":1,"score":0.3438807725906372},{"id":"https://openalex.org/C144133560","wikidata":"https://www.wikidata.org/wiki/Q4830453","display_name":"Business","level":0,"score":0.33247822523117065},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.1857644021511078},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.0},{"id":"https://openalex.org/C2777138892","wikidata":"https://www.wikidata.org/wiki/Q415264","display_name":"Infliximab","level":3,"score":0.0}],"mesh":[],"locations_count":3,"locations":[{"id":"pmh:oai:figshare.com:article/21583287","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/dataset/Supplementary_Material_for_Effectiveness_and_Safety_of_Golimumab_in_the_Treatment_of_Ulcerative_Colitis_52-week_Results_from_Post-marketing_Surveillance_in_Japan/21583287","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Dataset"},{"id":"doi:10.6084/m9.figshare.21583287","doi":"https://doi.org/10.6084/m9.figshare.21583287","is_oa":true,"landing_page_url":"https://doi.org/10.6084/m9.figshare.21583287","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Dataset"},{"id":"doi:10.6084/m9.figshare.21583287.v1","doi":"https://doi.org/10.6084/m9.figshare.21583287.v1","is_oa":true,"landing_page_url":"https://doi.org/10.6084/m9.figshare.21583287.v1","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Dataset"}],"best_oa_location":{"id":"pmh:oai:figshare.com:article/21583287","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/dataset/Supplementary_Material_for_Effectiveness_and_Safety_of_Golimumab_in_the_Treatment_of_Ulcerative_Colitis_52-week_Results_from_Post-marketing_Surveillance_in_Japan/21583287","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Dataset"},"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4309467170","https://openalex.org/W4206942807","https://openalex.org/W3187607915","https://openalex.org/W4200511578","https://openalex.org/W4414559262","https://openalex.org/W3215674896","https://openalex.org/W2883864835","https://openalex.org/W3015877068","https://openalex.org/W2566144010","https://openalex.org/W4387543414"],"abstract_inverted_index":{"Introduction:":[0],"Real-world":[1],"evidence":[2],"for":[3,35,92],"the":[4,27,112,203],"effectiveness":[5,29,93,220],"and":[6,30,64,67,88,101,108,183,228],"safety":[7,31,74,232],"of":[8,21,32,146,187,199,205,221,234],"golimumab":[9],"(GLM)":[10],"in":[11,46,51,81,111,125,179,192,226],"patients":[12,48,131,181,194],"with":[13,49,171,209,239],"ulcerative":[14],"colitis":[15],"(UC)":[16],"is":[17,44],"limited.":[18],"The":[19,73,218,231],"aim":[20],"this":[22],"study":[23,43],"was":[24,97,120,166,207,224,237],"to":[25],"investigate":[26],"52-week":[28],"GLM":[33,222,235],"treatment":[34,68,223,236],"UC.":[36],"Methods:":[37],"This":[38],"prospective,":[39],"multicentre,":[40],"post-marketing":[41],"surveillance":[42],"conducted":[45],"393":[47],"UC":[50,200],"Japan":[52],"(UMIN000027542).":[53],"Clinical":[54,95],"remission":[55,83,96,119,142,173],"(partial":[56],"Mayo":[57],"score":[58],"\u22642),":[59],"adverse":[60],"drug":[61],"reactions":[62],"(ADRs)":[63],"their":[65],"predictors,":[66],"persistence":[69],"were":[70,86,90],"analysed.":[71],"Results:":[72],"analysis":[75,152],"sets":[76],"comprised":[77],"391":[78],"patients.":[79,127],"Patients":[80],"clinical":[82,118,141,172],"at":[84,103,136,174],"baseline":[85,137],"excluded,":[87],"336":[89],"used":[91,134],"analysis.":[94,114],"47.9%,":[98],"48.5%,":[99],"44.6%,":[100],"39.6%":[102],"weeks":[104],"6,":[105],"22,":[106],"36,":[107],"52,":[109,130],"respectively,":[110],"intent-to-treat":[113],"In":[115],"biologic-na\u00efve":[116,227],"patients,":[117],"slightly":[121],"higher":[122],"than":[123,144],"that":[124,154],"biologic-experienced":[126],"At":[128],"week":[129,175],"who":[132],"concomitantly":[133],"corticosteroids":[135,147],"showed":[138,153],"numerically":[139],"lower":[140],"rates":[143],"non-users":[145],"(34.9%":[148],"vs":[149],"44.5%).":[150],"Multivariate":[151],"smoking":[155],"history":[156],"(P=0.040,":[157],"odds":[158],"ratio":[159],"[OR]=1.911,":[160],"95%":[161,214],"confidence":[162],"interval":[163],"[CI]":[164],"1.030\u20133.546)":[165],"an":[167],"independent":[168],"factor":[169],"associated":[170,208],"52.":[176],"ADRs":[177,190],"occurred":[178,191],"71":[180],"(18.2%)":[182],"included":[184],"9":[185],"cases":[186,198],"rash.":[188],"Serious":[189],"40":[193],"(10.2%),":[195],"including":[196],"8":[197],"exacerbation.":[201],"Additionally,":[202],"presence":[204],"comorbidities":[206],"ADR":[210],"incidence":[211],"(P=0.010,":[212],"OR=2.000,":[213],"CI":[215],"1.183\u20133.380).":[216],"Conclusion:":[217],"real-world":[219],"confirmed":[225],"-experienced":[229],"populations.":[230],"profile":[233],"consistent":[238],"previous":[240],"findings.":[241]},"counts_by_year":[],"updated_date":"2026-10-08T09:06:37.294493","created_date":"2024-04-08T00:00:00"}